SHENK KEVIN D.,PARLATI FRANCESCO,ZHOU HAN-JIE,SYLVAIN CATHERINE,SMYTH MARK S.,BENNETT MARK K.,LAIDIG GUY J.,SHENK Kevin D.,PARLATI Francesco,ZHOU Han-jie,SYLVAIN Catherine,SMYTH Mark S.,BENNETT Mark K.,LAIDIG GUY J
申请号：
SI200731257
公开号：
SI2041158T1
申请日:
2007.06.19
申请国别(地区):
SI
年份:
2013
代理人:
摘要：
One aspect of the invention relates to inhibitors of formula (I) that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
